MLYS Live signals | Maximize Profits with Getagraph.com

SELL 111148 min ago

@ $14.51

Issued: 14 Feb 2024 @ 09:37

Return: -7.20%

Previous signal: Feb 12 - 15:27

Previous signal: Buy

Return: -1.46 %

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 15:05):

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases...

Stats
Today's Volume	58 379.00
Average Volume	166 059
Market Cap	668.53M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.680 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.77
ATR14	$0.0370 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Rodman David Malcom	Sell	6 349	Stock Option
2024-04-12	Rodman David Malcom	Buy	6 349	Common Stock
2024-04-11	Rodman David Malcom	Buy	5 017	Common Stock
2024-04-11	Rodman David Malcom	Sell	5 017	Stock Option
2024-03-12	Rodman David Malcom	Sell	6 348	Stock Option

INSIDER POWER
-37.02
Last 64 transactions
Buy: 11 251 138 \| Sell: 35 554 805

Volume Correlation

Long: -0.22 (neutral)

Short: 0.62 (weak)

Signal:(75.924) Neutral

Mineralys Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mineralys Therapeutics, Correlation - Currency/Commodity

0.81
( strong )

0.80
( strong )

-0.68
( moderate negative )

0.54
( weak )

-0.35
( neutral )

Mineralys Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.990

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.990

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Mineralys Therapeutics,

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.